Paradigms hay fever clinical trial cleared to commence
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Appendix 4C - September 2016 quarter
- Paradigms Placement heavily oversubscribed
- Preclinical study underpins efficacy of Paradigms RhinosulR
- Paradigm PPS a potential in the treatment of viral arthritis
- Preliminary Final Report
Later from Paradigm Biopharmaceuticals
- Recruitment complete in Paradigms hay fever clinical trial
- Quarterly Cashflow Report
- Paradigm Update Ross River Virus Clinical Trial
- Paradigm receives $1.34 million R&D tax incentive rebate
- Final participant treated in Phase 2 hay fever trial
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals